Skip to content
Clinical Trials – home

Vita Longa Sp. z o.o.

Research site

Poland Ul. Uniczowska 6, 40-748 Katowice, Poland

  • 22 trials recruiting
  • Colitis ulcerative · Crohn's disease · Atrial fibrillation
  • Adults and children

About Specializations

Vita Longa Sp. z o.o. in Katowice, Poland specialises in clinical trials of conditions such as Colitis ulcerative, Crohn's disease, Atrial fibrillation, Obesity, and other specialisations. This site conducts important research.

Main research areas of the site

Gastroenterology and Inflammatory Bowel Disease

At Vita Longa Sp. z o.o. in Katowice, a major share of research focuses on digestive system diseases, especially ulcerative colitis and Crohn’s disease. These studies are designed to assess new treatment options, improve disease control, and better define how remission can be achieved and maintained.

  • Clinical research in ulcerative colitis aims to evaluate new therapies for inducing and maintaining remission.
  • Studies in Crohn’s disease explore whether novel treatments can improve bowel healing and symptom control.
  • Several trials assess the effectiveness and safety of approaches for inflammatory bowel disease.

This area reflects a strong clinical interest in advancing care for chronic intestinal inflammation and improving outcomes for patients with complex gastrointestinal conditions.

Heart Failure and Cardiovascular Research

The site also contributes to cardiovascular diseases research, with trials in heart failure, hypertension, and broader cardiovascular risk reduction. The main goal is to test whether new therapies can lower complications and support better long-term heart health.

  • Research in heart failure examines treatment strategies for patients with reduced or preserved ejection fraction.
  • Trials in type 2 diabetes and cardiovascular risk study ways to prevent heart-related events.
  • Some studies focus on inflammation-linked heart disease and the prevention of worsening cardiac outcomes.

This portfolio shows an active interest in improving treatment effectiveness for people living with chronic cardiac conditions.

Skin, Allergy, and Immune-Mediated Conditions

Another prominent area at this hospital/clinic is research into skin and connective tissue diseases and immune system diseases, including acne vulgaris, psoriasis, atopic dermatitis, chronic spontaneous urticaria, and allergic rhinoconjunctivitis. These trials are focused on testing new treatments and improving symptom relief for conditions that often affect daily quality of life.

  • Studies in psoriasis and atopic dermatitis evaluate whether new therapies can better control skin inflammation.
  • Research in acne vulgaris looks at long-term safety and effectiveness of topical treatment options.
  • Allergy-related trials aim to reduce birch pollen-induced rhinoconjunctivitis symptoms and medication use.

These projects highlight a broad effort to improve care for immune-driven skin and allergy disorders through more effective and better-tolerated treatments.

Neurology, Pain, and Metabolic Disorders

The research program also covers nervous system diseases, musculoskeletal diseases, and nutritional and metabolic diseases. Key studies involve migraine, chronic low back pain, diabetic neuropathic pain, gastroparesis, and obesity, with a clear emphasis on evaluating therapies that may ease symptoms and improve everyday functioning.

  • Trials in migraine investigate both prevention and acute symptom relief.
  • Studies in chronic non-specific low back pain and neuropathic pain assess new options for pain reduction.
  • Research on gastroparesis and obesity explores whether emerging treatments can improve digestive symptoms and metabolic health.

This mix of studies shows a practical focus on conditions that can significantly affect comfort, mobility, and day-to-day wellbeing.

Women’s Health and Other Specialized Studies

Vita Longa Sp. z o.o. also participates in research on female urogenital diseases and pregnancy complications, including endometriosis-related pain and oral contraception. In addition, some trials address rheumatoid arthritis and systemic lupus erythematosus, reflecting a wider interest in chronic inflammatory diseases.

  • Women’s health studies examine new approaches for endometriosis pain and contraceptive-related outcomes.
  • Autoimmune disease trials evaluate potential therapies for rheumatoid arthritis and systemic lupus erythematosus.
  • These studies aim to improve treatment effectiveness while also monitoring safety and tolerability.

The site’s portfolio combines targeted specialty care with broader clinical research in chronic, immune-mediated, and symptom-driven conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ul. Uniczowska 640-748 KatowicePoland
Recruiting now
22 trials
Conditions studied
37

More sites in KatowicePoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

62 clinical trials

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
  • Sponsor:Novo Nordisk A/S

Contraception+1

Recruiting

Contraceptive efficacy, safety and tolerability of drospirenone 4 mg (LPRI‑CF113) in healthy women of reproductive age over 13 cycles

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · Healthy volunteers
  • Substances:Drospirenone
  • Sponsor:Chemo Research S.L.

Phase 2 Randomized Double‑Blind Placebo‑Controlled Study of MH002 in Adults with Mild‑to‑Moderate Ulcerative Colitis Inadequately Controlled by 5‑ASA

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.

Crohn's disease

Recruiting

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Crohn's disease

Recruiting

A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A study testing XmAb942 compared to placebo in adults with moderate-to-severe active ulcerative colitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:XMAB942
  • Sponsor:Xencor Inc.

A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:SPY002
  • Sponsor:Spyre Therapeutics Inc.

A study of duvakitug for patients with moderately to severely active ulcerative colitis to see if it works and is safe as maintenance therapy

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A study testing duvakitug for patients with moderately to severely active ulcerative colitis

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.